上海交通大学学报(医学版) ›› 2017, Vol. 37 ›› Issue (9): 1226-.doi: 10.3969/j.issn.1674-8115.2017.09.007

• 论著(基础研究) • 上一篇    下一篇

血清 miR-499 和 miR-652用于急性冠脉综合征早期诊断的临 床试验#br#

曹惠敏,尤纱纱,薛雨晨,何斌   

  1. 上海交通大学 医学院附属新华医院麻醉与重症医学科,上海 200092
  • 出版日期:2017-09-28 发布日期:2017-10-10
  • 通讯作者: 何斌,电子信箱:hebin@xinhuamed.com.cn
  • 作者简介:曹惠敏(1992—),男,硕士生;电子信箱:caohuimin0330@163.com
  • 基金资助:
    国家自然科学基金(81470390);上海市教育委员会高峰高原学科建设计划(20152218);上海申康临床三年行动计划(16CR3006A)

Clinical trial of serum miR-499 and miR-652 for early diagnosis of acute coronary syndrome#br#

CAO Hui-min, YOU Sha-sha, XUE Yu-chen, HE Bin   

  1. Department of Anesthesiology and SICU, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
  • Online:2017-09-28 Published:2017-10-10
  • Supported by:
    National Natural Science Foundation of China, 81470390; Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support, 20152218; Clinical Research Plan of SHDC, 16CR3006A

摘要: 目的 · 评估血清 miRNA 用于急性冠脉综合征(ACS)早期诊断的潜在价值。方法 · 急诊入院的 28 例疑似 ACS 患者,在 3 h 内采集血液样本;根据ACS 诊疗指南,最终将患者分为ACS 组(18 例)和非ACS 组(10 例)。采用qRT-PCR 技术检测心肌特异 性 miR-499 以及与心肌损伤密切相关的 miR-652 的含量,同时监测肌钙蛋白 I(cTnI)变化,分析 miRNA 和 cTnI 之间的相关性,并 采用95% 界值建立医学参考值范围。结果 · 研究对象急诊入院3 h 内,ACS 患者的血清中已检测到miRNA 的升高;并且ACS 组 患者血清miR-499 的表达水平为非ACS 组的9.2 倍(P=0.009)。 miR-499(r=0.595,P=0.001)和miR-652(r=0.579,P=0.001)均 与 cTnI 呈显著正相关;miR-499 和 miR-652 的 ROC 曲线下面积(AUC)分别为0.786 和 0.583;miR-499 的敏感度与特异度分别为 72.22% 和 80.00%,miR-652 则为72.22% 和 60.00%;miR-499 和 miR-652 医学参考值范围分别为0.001 ~ 2.723 和 0.122 ~ 9.660。
 结论 · 血清中的心肌特异性 miR-499 有望成为 ACS 早期诊断的生物标志物。

关键词: 微小 RNA, 急性冠脉综合征, miR-499, miR-652, 肌钙蛋白 I, 生物标志物, 临床试验

Abstract: Objective · To investigate the potential value of serum miRNAs for early diagnosis of acute coronary syndrome (ACS).  Methods · Blood samples were collected from 28 emergency patients with suspected ACS in 3 h after enrollment. Eighteen patients were finally diagnosed as ACS and ten as nonACS according to the ACS guideline. The expression levels of cardiac miR-499 and myocardial injury related miR-652 were measured with qRT-PCR. At the same time levels of troponin I (cTnI) were monitored. Then the correlations between miRNAs and cTnI were analyzed. In addition, 95% reference range was established.  Results · The expression levels of serum miRNAs increased in ACS patients within 3 h and serum miR-499 in the ACS patients was 9.2 times the amount in the non-ACS patients (P=0.009). Serum miR-499 (r=0.595, P=0.001) and miR-652 (r=0.579, P=0.001) levels both had positive correlations with cTnI. The area under the ROC curve (AUC) of serum miR-499 and miR-652 was 0.786 and 0.583, respectively. The sensitivity and specificity of miR-499 were 72.22% and 80.00%, respectively, while 72.22% and 60.00% for miR-652. The reference ranges of serum miR-499 and miR-652 were 0.001-2.723 and 0.122-9.660, respectively.  Conclusion · Cardiac miR-499 in serum has potential to be a biomarker for early diagnosis of ACS.

Key words:  microRNA, acute coronary syndrome, miR-499, miR-652, troponin I, biomarker, clinical trial